HEART FAILURE NETWORK

Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction (RELAX):

A Randomized Clinical Trial

Margaret M Redfield, MD
on behalf of the
NHLBI Heart Failure Clinical Research Network

U.S. Department of Health and Human Services
National Institutes of Health

National Heart Lung and Blood Institute
People Science Health

Background

- Phosphodiesterase type-5 (PDE-5) metabolizes nitric oxide (NO) and natriuretic peptide (NP) generated cGMP
- If PDE-5 is activated in HF; may limit beneficial NO and NP actions in the heart, vasculature and kidney
- PDE-5 Inhibitor therapy approved for
  - *Erectile dysfunction*
  - *Group I pulmonary arterial hypertension (PAH*)
- Role in heart failure (HF) with reduced (HFrEF) or preserved (HFpEF) ejection fraction unclear

Background

- **Experimental HF:** PDE-5 inhibition
  - *Reversed cardiac remodeling and dysfunction*
  - *Improved vascular and renal function*
- **Small Clinical Studies:** PDE-5 inhibition (sildenafil)
  - *HFrEF*

    Improved maximal exercise capacity
  - *HFpEF + PAH + RV dysfunction*

    Improved hemodynamics, lung function, RV function and LV remodeling

Hypothesis

In comparison to placebo, chronic (24 weeks) therapy with the PDE-5 inhibitor sildenafil will improve exercise capacity (peak VO_2) and clinical status in HFpEF.

Study population

- NYHA class II-IV HF symptoms
- EF ≥ 50%
- Objective evidence of HF (at least one)
  - *HF hospitalization or ED visit + iv diuretic*
  - *Elevated PCWP at catheterization for dyspnea*
  - *Left atrial enlargement + chronic diuretic for HF*
- At study entry (both)
  - *Peak VO_2 < 60% age/sex nl value + RER ≥ 1.0*
  - *NT-proBNP*
    - *≥ 400 pg/ml **or***
    - *< 400 pg/ml with documented ↑ PCWP ≤ two weeks of NT-proBNP < 400*

Study Design



Study Endpoints

- **Primary Endpoint**
  - *Change in peak VO_2 after 24 weeks of therapy*
- **Secondary Endpoints**
  - *Change in 6MWD after 24 weeks of therapy*
  - *Hierarchical composite clinical rank score*
- **Other Endpoints**
  - *Change in CV structure and function (24 weeks)*
    Echo-Doppler
    Cardiac magnetic resonance imaging (CMR)
  - *Change in biomarkers (24 weeks)*

Hierarchical composite clinical rank score

At 24 weeks, all patients ranked

1	**FIRST** Death
X	**LAST** Death

Hierarchical composite clinical rank score

HEART FAILURE NETWORK

At 24 weeks, all patients ranked

1	**FIRST** Death
X	**LAST** Death
X+1	Alive with **FIRST** CV or cardiorenal hsp
Y	Alive with **LAST** CV or cardiorenal hsp

Hierarchical composite clinical rank score

HEART FAILURE NETWORK

At 24 weeks, all patients ranked

1	**FIRST** Death
X	**LAST** Death
X+1	Alive with **FIRST** CV or renal hospitalization
Y	Alive with **LAST** CV or renal hospitalization
Y+1	**LEAST** favorable change in MLHFQ
Z	**MOST** favorable change in MLHFQ

Mean rank score (lower worse) compared between treatment groups
Anchor value (no treatment effect) = Z / 2

Baseline Features

Characteristic	Placebo (N = 103)	Sildenafil (N = 113)
Age (years)	69	68
Female	53%	43%
White race	92%	90%
BMI (kg/m^2)	33	33
NYHA class II/III	45% / 55%	49% / 51%
HF hospitalization in past year	39%	35%
Hx hypertension	90%	80%*
Hx of coronary artery disease	36%	42%
Diabetes	44%	42%
Hx of atrial fibrillation	50%	52%

Median values or % shown

****p-value < 0.05***

Baseline Features

Characteristic	Placebo (N = 103)	Sildenafil (N = 113)
Ejection fraction (%)	60	60
NT-proBNP (pg/ml)	648	757
Peak VO2 (ml/kg/min) (% predicted)	11.9 (41%)	11.7 (41%)
Chronotropic incompetence present	78%	76%
6MWD (m) (% predicted)	305 (68%)	308 (70%)
Cardiac index (L/min/m^2) - *(normal > 2.5)*	2.48	2.47
Relative Wall Thickness ≥ 0.42	44%	48%
E/e' - *(normal ≤ 8)*	17	15
LA volume index (ml/m^2) - *(normal < 29)*	43	44
PASP (mmHg) - *(normal < 30)*	41	41

Median values or % shown

All p > 0.05

Results:

Results: Primary Endpoint



Withdrew consent (n=14), death (n=3), unwilling (n=3) or unable (n=9) to complete CPXT, inadequate peak VO_2 data (n=2)

Results: Primary Endpoint



Sensitivity analyses for missing data

Multiple imputation: p = 0.98; LOCF: p = 0.98

Data are median and IQR

Results: Secondary Endpoints



Data are median and IQR

Results: Secondary Endpoints



Results: Safety

Characteristic	Placebo	Sildenafil
Death (%)	0%	3%
CV or cardiorenal hospitalization (%)	13%	13%
Adverse events (%)	76%	80%
Serious adverse events (%)	16%	22%
Withdrew or Unwilling or Unable to complete 24 week CPXT	8%	16%

All p > 0.05

Results: Other endpoints

Characteristic	Placebo	Sildenafil
Change in LV mass by CMR (g)	0.6	-1.5
Change in E/e’	-1.6	0.2
Change in PASP (mmHg)	-2	2
Change in creatinine (mg/dl)	0.01	0.05*
Change in cystatin C (mg/L)	0.01	0.05*
Change in NT-proBNP (pg/ml)	-23	15*
Change in endothelin-1 (pg/ml)	-0.01	0.38*
Change in uric acid (mg/dl)	-0.01	0.30*

p-value < 0.05

Median values shown

Conclusions

- Chronic therapy with the PDE-5 inhibitor sildenafil was not associated with clinical benefit in HFpEF
- Continued efforts to identify key pathophysiologic perturbations and novel therapeutic targets in HFpEF are needed

HEART FAILURE NETWORK



Margaret M. Redfield, MD
Horng H. Chen, MD
Barry A. Borlaug, MD
Marc J. Semigran, MD
Kerry L. Lee, PhD
Gregory Lewis, MD
Martin M. LeWinter, MD
Jean L. Rouleau, MD
David A. Bull, MD
Douglas L. Mann, MD
Anita Deswal, MD
Lynne W. Stevenson, MD
Michael M. Givertz, MD
Elizabeth O. Ofili, MD
Christopher M. O'Connor, MD
G. Michael Felker, MD
Steven R. Goldsmith, MD
Bradley A. Bart, MD
Steven E. McNulty, MS
Jenny C. Ibarra, MSN
Grace Lin, MD
Jae K. Oh, MD
Manesh R. Patel, MD
Raymond J. Kim, MD
Russell P. Tracy, PhD
Eric J. Velazquez, MD
Kevin J. Anstrom, PhD
Adrian F. Hernandez, MD
Alice M. Mascette, MD
Eugene Braunwald, MD
for the RELAX Trial

HEART FAILURE NETWORK

ONLINE FIRST

Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction

A Randomized Clinical Trial

JAMA, Published online March 11, 2013